iosBio appoints Patricia Londono-Hayes as Chief

Oral vaccines and biotherapeutics company strengthens senior leadership team with new role to

drive priority development programmes

Burgess Hill, UK, 14 June 2021—iosBio (‘the Company’), a UK-based biotechnology company

developing next-generation vaccines that can be administered orally, today announces the

appointment of Patricia Londono-Hayes, PhD, as Chief Development Officer.

With more than 20 years of experience in the pharmaceutical and biotechnology sector, Patricia is a

leader in vaccines and biologics product development. She brings extensive experience in the

progression of vaccine candidates from initial concept into first-in-human testing, advancement of

clinical development and licensing.

In her role, Patricia will lead the development and execution of iosBio’s pipeline strategy, as the

Company moves into its next stage of growth. In January 2021 iosBio signed an exclusive worldwide

licensing agreement granting ImmunityBio rights to its OraPro™ vaccine platform technology for the

oral delivery of ImmunityBio’s second-generation human Adeno (hAd5) COVID-19 vaccine

candidate. iosBio’s second priority programme, OraPro-Flu – a thermally stable, orally-delivered,

quadrivalent seasonal influenza vaccine – is currently in preclinical studies and expected to enter

the clinic later this year.

Across her career, Patricia has directed global programmes, teams, and partnerships at scientific,

strategic, and operational levels, contributing to the development and licensing of vaccines spanning

a broad range of indications including influenza and a variety of respiratory, gastro-intestinal, genitourinary,

and nosocomial infections.

Patricia joins iosBio from Sanofi Pasteur, where she held positions of increasing responsibility, most

recently as Head of External R&D Initiatives and Scientific Affairs, Europe, where she led the strategy

and implementation of external R&D public‐private partnerships and alliances. During her tenure,

she spearheaded multi million Euro investments in R&D partnerships between the company and

other vaccine manufacturers, leading academic institutions, the EU and the Gates Foundation. Prior

to that, she was Head of Global Preclinical Research & Development Department and Leader of the

Universal Influenza Vaccine Project at the company, overseeing, translational, preclinical, and

clinical pharmacology research. Before joining Sanofi Pasteur, Patricia worked at vaccine company

Acambis, where she founded and directed the Immunology Research Department and initiated

research programs in oral vaccines.

She gained her PhD in Biochemistry and Immunology from Imperial College London and holds an

MSc in Molecular Biology and Genetic Manipulation and a BSc in Microbiology from the University

of Sussex and University of Los Andes, respectively.

Executive Chairman of iosBio, Wayne Channon said: “With her impressive track record in

vaccine development, I am delighted to welcome Patricia to iosBio. Her breadth of experience in

leading vaccines programmes from idea through to clinical development will be critical as we pursue

our mission to lead the way in next generation, oral vaccines.”

Page 2 of 2

Patricia Londono-Hayes commented: “I am thrilled to be joining iosBio at such an exciting stage,

with the Company’s OraPro™ vaccine platform technology being investigated in trials of what could

be the first oral COVID-19 vaccine. iosBio’s science has the potential to truly transform vaccine

development and to overcome the global challenges of traditional vaccines. I am delighted to be

joining such an experienced and innovative team and look forward to working together on IosBio’s

vision to bring orally administered, thermally stable vaccines to people around the world.”

Ends

For further information please contact:

Consilium Strategic Communications

Mary-Jane Elliott, Melissa Gardiner, David Daley

IosBio@consilium-comms.com

Tel: +44 (0) 20 3709 5700

NOTES FOR EDITORS

About iosBio

iosBio is a UK based biotechnology company developing next generation vaccines that can be

administered orally.

The Company’s proprietary OraPro™ thermal stabilization technology enables the oral

administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via

the gastrointestinal (GI) tract and other routes. These vaccine vectors are engineered to withstand

temperatures of up to 50 degrees and the hostile conditions in the stomach without loss of efficacy

and providing long term product stability at ambient temperatures.

iosBio is developing vaccines designed to stimulate mucosal, systemic and T cell immune

responses, providing robust immunity to a number of infectious diseases including COVID-19, Zika

and influenza.

In January 2021 iosBio announced an exclusive worldwide licensing agreement with ImmunityBio,

Inc. a US-based, privately held clinical-stage immunotherapy company, for iosBio’s OraPro™

vaccine platform technology currently being investigated in a Phase Ib trial of ImmunityBio’s secondgeneration

human Adeno (hAd5) COVID-19 vaccine candidate.

iosBio is headquartered in Burgess Hill, UK. For more information visit: iosbio.com

Development Officer

 

Sydney Morning Herald – Game-changing COVID-19 vaccine pill pursued by small British firm

LinkedIn

In an interview with @Bevan Shields at the @Sydney Morning Herald, our Chairman @Wayne Channon discussed the potential of oral vaccines to revolutionize the fight against infectious diseases like COVID-19, providing a more targeted immune response and overcoming the need for storage and transportation at freezing temperatures.

Read the full article: [Link]

#COVID19 #OralVaccines

Twitter

Great to be featured in the @smh, discussing how oral vaccines can revolutionize the fight against COVID-19, overcoming the need for cold chain storage and providing a more targeted immune response.

Read the full article: [LINK]

#COVID19 #OralVaccines

Follow us

Keep up to date with our news and find out more about investment opportunities with iosBio.

The team of doctors and scientists at iosBio believe that the next great leap forward in immunization will be oral delivery


Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.

    We will not, in any circumstances share your personal information with other individuals or organizations without your permission.